DDX5 and neoplasm: However, to maximise the future clinical outcome of FL118 application and to understand the detailed FL118 MOA, further studies are required to assess targeting DDX5 by FL118 alone (most patients would be enough) or in combination with appropriate chemotherapeutic agents (for some patients who have a low‐level expression of DDX5 in their PDAC or CRC tumours).